| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2010 | 2009 | 2008 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16,3 M € | -70.4% | 55,2 M € | +12.4% | 49,1 M € | +10.0% | 44,7 M € | +1.4% | 44,1 M € | -27.6% | 60,9 M € | -0.7% | 61,3 M € | -14.0% | 71,3 M € | +13.9% | 62,6 M € | -10.6% | 70,1 M € | +43.6% | 48,8 M € | +665.3% | 6,4 M € | +178.3% | 2,3 M € | — | — | — | — | |||||
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — | — | 815,0 k € | +6.0% | 769,0 k € | +71.1% | 449,5 k € | -37.0% | 713,7 k € | ||||||||||||||
| EBITDA | 997,0 k € | -95.3% | 21,0 M € | +21.1% | 17,4 M € | +55.3% | 11,2 M € | +106.0% | -187,3 M € | -1088.5% | 19,0 M € | -20.4% | 23,8 M € | -48.9% | 46,6 M € | +152.9% | -88,1 M € | -284.8% | 47,7 M € | +79.6% | 26,5 M € | +779.9% | 3,0 M € | +132.0% | 1,3 M € | +59.6% | 814,6 k € | +6.5% | 764,6 k € | +71.0% | 447,1 k € | -37.2% | 711,6 k € | |
| Operating profit | -545,8 k € | -106.1% | 9,0 M € | +313.1% | 2,2 M € | +145.5% | -4,8 M € | +97.9% | -227,5 M € | -388.6% | -46,6 M € | -63.5% | -28,5 M € | -325.6% | -6,7 M € | +95.3% | -141,5 M € | -1244.9% | -10,5 M € | -45.3% | -7,2 M € | -322.9% | -1,7 M € | -256.8% | 1,1 M € | +35.6% | 805,6 k € | +6.1% | 759,1 k € | +75.4% | 432,7 k € | -38.0% | 698,3 k € | |
| Profit/loss | 11,4 M € | +16.7% | 9,7 M € | +390.0% | 2,0 M € | +120.2% | -9,9 M € | +94.7% | -186,1 M € | -309.1% | -45,5 M € | -59.3% | -28,6 M € | -301.4% | -7,1 M € | +95.0% | -142,5 M € | -340.8% | -32,3 M € | -522.3% | 7,7 M € | +538.2% | -1,7 M € | -278.8% | 977,2 k € | +31.6% | 742,3 k € | -7.6% | 803,6 k € | +400.7% | 160,5 k € | -72.8% | 589,1 k € | |
| Equity | 240,2 M € | +92.7% | 124,6 M € | +1.0% | 123,4 M € | +1.6% | 121,4 M € | -55.8% | 274,8 M € | -40.4% | 460,9 M € | -9.0% | 506,4 M € | -5.3% | 534,9 M € | -1.3% | 542,0 M € | -20.8% | 684,6 M € | +32.5% | 516,6 M € | +10.6% | 467,3 M € | +35988.6% | 1,3 M € | +307.7% | 317,6 k € | +175.5% | 115,3 k € | +3.3% | 111,7 k € | -82.9% | 651,1 k € | |
| Total assets | 246,6 M € | +61.4% | 152,8 M € | +4.9% | 145,7 M € | +2.6% | 141,9 M € | -60.2% | 356,7 M € | -24.5% | 472,4 M € | -8.9% | 518,5 M € | -7.3% | 559,0 M € | -8.4% | 610,1 M € | -21.9% | 781,2 M € | +23.7% | 631,4 M € | +34.2% | 470,6 M € | +12256.3% | 3,8 M € | +202.9% | 1,3 M € | +2.1% | 1,2 M € | -12.2% | 1,4 M € | +39.1% | 1,0 M € | |
| Cash | 7,2 k € | +305.9% | 1,8 k € | 0.0% | 1,8 k € | 0.0% | 1,8 k € | 0.0% | 1,8 k € | -85.5% | 12,3 k € | +591.9% | 1,8 k € | 0.0% | 1,8 k € | -0.0% | 1,8 k € | 0.0% | 1,8 k € | 0.0% | 1,8 k € | — | — | 97,7 k € | +5648.2% | 1,7 k € | -99.8% | 712,2 k € | +249.9% | 203,5 k € | ||||
| Debts | 6,4 M € | -77.2% | 28,0 M € | +40.7% | 19,9 M € | -0.1% | 19,9 M € | -75.2% | 80,3 M € | +679.2% | 10,3 M € | -6.9% | 11,1 M € | -52.7% | 23,4 M € | -62.9% | 63,1 M € | -29.3% | 89,3 M € | -22.1% | 114,5 M € | +3391.6% | 3,3 M € | +30.5% | 2,5 M € | +167.7% | 938,6 k € | -15.8% | 1,1 M € | -13.6% | 1,3 M € | +261.9% | 356,5 k € | |
| Staff | 38,2 | 43,1 | 44,5 | 46,7 | 47 | 44,5 | 43,2 | 41,9 | 37,9 | 27,5 | 13,6 | 2,4 | — | — | — | — | — | |||||||||||||||||
Public limited company · Gent · incorporated on 09/10/2006 · 38,2 ETP
Public limited company profitable and well capitalised. Cash position rising (+305.9%).
Solid counterparty for a standard engagement.
OMEGA PHARMA INNOVATION & DEVELOPMENT is a Public limited company incorporated in 2006. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent. It employs on average 38,2 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette